Modality
Gene Editing
MOA
WEE1i
Target
CD47
Pathway
Innate Imm
Wet AMD
Development Pipeline
Preclinical
~Aug 2020
→ ~Nov 2021
Phase 1
Feb 2022
→ Jul 2026
Phase 1Current
NCT08755735
1,188 pts·Wet AMD
2022-02→2026-07·Not yet recruiting
1,188 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-254mo awayPh2 Data· Wet AMD
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1/2
Not yet…
Catalysts
Ph2 Data
2026-07-25 · 4mo away
Wet AMD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08755735 | Phase 1/2 | Wet AMD | Not yet recr... | 1188 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |